[Primary and secondary prevention of coronary artery disease].
Mohri
Masahiro
M
Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage; D003324:Coronary Artery Disease / Q000209:etiology / Q000517:prevention & control*; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000628:therapy; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000628:therapy; D006973:Hypertension / Q000150:complications / Q000628:therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008019:Life Style; D017410:Practice Guidelines as Topic; D011322:Primary Prevention; D012307:Risk Factors
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000960:Hypolipidemic Agents; D001241:Aspirin